PCI Pharma to invest in new clinical facility in Dublin

29th August 2019 (Last Updated December 22nd, 2019 15:20)

PCI Pharma is set to invest in a new clinical facility near Dublin, Ireland to significantly increase capabilities and capacity for its clinical services business.

PCI Pharma is set to invest in a new clinical facility near Dublin, Ireland to significantly increase capabilities and capacity for its clinical services business.This latest investment comes as part of the company’s overall global network expansion strategy.

Upon completion, the new facility will provide more than 75,000ft² of space. It serves as a key primary and secondary packaging, storage, logistics and distribution centre.

The expansion is expected to take place in the coming months. It will add extra controlled room temperature and cold chain storage capabilities for PCI customers and clinical packaging services.

The clinical facility, licensed by the Health Products Regulatory Authority (HPRA), provides clinical storage and distribution (S&D) towards the shipment of Investigational Medicinal Products (IMP) to global sites and those within the EU.

“Our growth strategy is focused on the continued expansion of our global network to support growing demand from our customers.”

The site will also provide additional services including cold chain handling, packaging and storage capabilities for clinical and commercial products and serialisation capability, as well as a full analytical release testing laboratory.

PCI said the new investment will allow it to expand its footprint in Dublin following the acquisition of Millmount Healthcare in 2017.

Since the acquisition, the company launched a dedicated high containment packaging facility used for commercial primary and secondary packaging. This facility will be used for packing solid oral dose forms including specialised and high potent products.

PCI Pharma CEO Salim Haffar said: “Our growth strategy is focused on the continued expansion of our global network to support growing demand from our customers and providing a solution for Brexit through ongoing investment in capacity, capability expansion and talent.”

The latest investment supports the company’s European expansion and Brexit plan to continue the supply of pharmaceuticals.

It will also complement PCI’s global clinical network across its Bridgend, UK, Rockford and San Diego, US and Melbourne, Australia sites.